rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    IFRX
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      12 Health Care Stocks Moving In Friday's After-Market Session
      Nov 13BenzingaIFRX
      Here's Why InflaRx (IFRX) Is a Great 'Buy the Bottom' Stock Now
      Nov 13Yahoo FinanceIFRX
      InflaRx Announces Publication of Phase 1 Data Demonstrating Favorable Safety and Pharmacokinetic/Pharmacodynamic Profile of Izicopan
      Nov 6Yahoo FinanceIFRX
      InflaRx Targets Kidney Protection, Steroid Reduction in AAV With Izicopan Trials
      Nov 3Yahoo FinanceIFRX
      InflaRx N.V. (IFRX) Analyst/Investor Day - Slideshow (NASDAQ:IFRX) 2026-11-03
      Nov 3Seeking AlphaIFRX
      InflaRx plans two phase 2 AAV trials starting in 2027
      Nov 3Investing.comIFRX
      InflaRx Highlights Izicopan Development Path and Commercial Opportunity in ANCA-Associated Vasculitis at Capital Markets Day

      With a goal of providing multiple data sets demonstrating differentiated efficacy and safety in multiple ANCA-associated vasculitis (AAV) settings, InflaRx intends to begin two Phase 2 trials in 2027, with first data readout anticipated in 2028Phase 2 AAV izicopan program expected to include a placebo-controlled randomized study in patients with renal involvement with site initiation in early 2027, as well as an open-label “all-comers” study to demonstrate the ability to replace corticosteroidsI

      Nov 3Yahoo FinanceIFRX
      InflaRx Announces November Investor Events

      Jena, Germany, Oct. 27, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced its events calendar for November. Guggenheim Securities 3rd Annual Healthcare Innovation ConferenceNovember 9 – 11, 2026 in Boston, MAFireside chat on November 10 at 9:30 AM ESTInflaRx will also conduct one-on-one investor meetings on November 10th. A link to view the fireside chat live stream and i

      Oct 27Yahoo FinanceIFRX
      Analysts Offer Insights on Healthcare Companies: Argenx Se (ARGX), InflaRx (IFRX) and Achieve Life Sciences (ACHV)

      Detailed price information for Achieve Life Sciences Inc (ACHV-Q) from The Globe and Mail including charting and trades.

      Oct 24The Globe and MailACHVIFRX
      InflaRx Highlights Izicopan’s Therapeutic Potential at Kidney Week 2026
      Oct 22Yahoo FinanceIFRX
      InflaRx to Present Late-Breaking Pre-clinical Data on Izicopan at Kidney Week 2026
      Oct 2Yahoo FinanceIFRX
      InflaRx appoints Gabriela Alperovich as head of clinical development
      Oct 1Investing.comIFRX
      InflaRx Appoints Gabriela Alperovich, MD, PhD, as Senior Vice President & Global Head of Clinical Development

      Jena, Germany, Oct. 01, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced the appointment of Gabriela Alperovich, MD, PhD, as Senior Vice President & Global Head of Clinical Development, effective October 1, 2026. Dr. Alperovich is a physician-scientist and nephrologist with more than two decades of experience in the global pharmaceutical industry, spanning senior leaders

      Oct 1Yahoo FinanceIFRX
      InflaRx to Host Virtual Capital Markets Day

      Event to be hosted on November 3, 2026 at 8:00 AM ESTFeatured speakers will include Peter A. Merkel, MD, MPH and Prof. Dr. Jörg Köhl Jena, Germany, Sept. 21, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it will host a virtual Capital Markets Event on November 3, 2026, from 8:00 AM EST / 2:00 PM CET to approximately 9:00 AM EST / 3:00 PM CET. The timing of the ev

      Sep 21Yahoo FinanceIFRX
      Needham Initiates InflaRx at Buy With $8 Price Target

      InflaRx N.V (IFRX) has an average rating of buy and mean price target of $7.92, according to analyst

      Sep 14Yahoo FinanceIFRX
      InflaRx at H.C. Wainwright conference: renal pivot takes center stage
      Sep 14Investing.comIFRX
      InflaRx at Cantor conference: renal pivot gains urgency
      Sep 9Investing.comIFRX

      This is the newest page. Registered accounts read further back.